NASDAQ$PODD

Insulet Corp. · Q4 2019 earnings

Q4 2019 earnings · · Investor relations

Briefing

Insulet's Q4 2019 revenue increased by 27% year-over-year, exceeding guidance. The company is on track to meet its 2021 financial targets.

Insulet Corporation reported a strong Q4 2019 with revenue reaching $209.4 million, a 27% increase year-over-year, exceeding the company's guidance. The company's Omnipod products saw significant growth, particularly in the US. Insulet is progressing towards its 2021 financial goals.

  • Q4 2019 revenue reached $209.4 million, a 27% increase year-over-year.
  • Total Omnipod revenue increased by 30% to $192.5 million.
  • U.S. Omnipod revenue increased by 36% to $126.7 million.
  • Net income was $5.0 million, or $0.08 per diluted share.

Headline financials

Total Revenue

$209M

Previous: $165M+27.0%
EPS (adj)

$0.08

Previous: $0.16-50.0%
Gross Margin

64.0%

No prior period
Capital Expenditures

$49.1M

Previous: $34.8M+41.2%
Free Cash Flow

-$2.18M

Previous: -$4.36M+49.9%
Net Income

$5M

Previous: $9.89M-49.5%
Operating Income

$18.2M

Previous: $16.2M+12.1%
Gross Profit

$134M

Previous: $110M+21.6%
Cash & Equivalents

$376M

Previous: $114M+230.2%
Total Assets

$1.14B

Previous: $929M+23.1%
Stock-Based Comp

$8M

Previous: $6.32M+26.6%

Revenue & EPS history

Insulet · Revenue · Quarterly

$209M

Q4 2019+27%vs Q4 2018
Beat estimate in 9 of 16 quarters(56%)
ActualEstimate

Revenue by segment

Insulet · $209M total across 3 segments · Q4 2019

  • U.S. Omnipod
    $127M
  • International Omnipod
    $65.8M
  • Drug Delivery
    $16.9M

Forward guidance

For the quarter ending March 31, 2020, the Company expects revenue growth of 17% to 20%, including a negative foreign currency impact of approximately 1%. Revenue growth ranges by product line are: Total Omnipod of 23% to 26%, including a negative foreign currency impact of approximately 1% U.S. Omnipod of 27% to 29% International Omnipod of 17% to 20%, including a negative foreign currency impact of approximately 3% Drug Delivery decline of 28% to 34%

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2019

Historical avgQ4 2019

+3.0%

Avg return

Earnings day

+4.0%

Avg return

5 days after

+5.2%

Avg return

30 days after

65%

41 / 63 earnings

Positive

+20.7%

Q1 2025

Best reaction

-16.8%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.1%+3.8%+1.4%
Q4 2025+3.5%+1.2%-7.8%
Q3 2025+2.8%+3.8%-3.2%
Q1 2025+20.7%+25.1%+21.3%
Q4 2024-1.9%-6.1%-6.9%
Q3 2024+12.0%+15.0%+10.9%
Q2 2024-4.3%+2.2%+12.8%
Q1 2024-5.5%-1.9%+9.0%
Q4 2023-4.3%-13.4%-14.6%
Q3 2023+18.1%+17.5%+39.6%
Q2 2023-11.9%-13.6%-31.6%
Q1 2023+2.4%-0.4%-12.4%
Q4 2022+2.3%-4.0%+7.8%
Q3 2022+19.6%+16.3%+17.7%
Q2 2022+2.4%-0.8%-2.5%
Q1 2022-16.8%-23.0%-13.9%
Q4 2021+8.9%+12.9%+7.4%
Q3 2021-1.3%+2.0%-15.6%
Q2 2021-1.3%+0.1%+8.4%
Q1 2021-11.4%-13.0%+2.8%
Q4 2020+2.3%+1.0%+1.0%
Q3 2020+14.6%+14.4%+16.0%
Q2 2020+1.1%-7.7%-4.9%
Q1 2020+5.4%+6.8%-13.3%
Q4 2019-13.2%-8.4%-14.2%
Q3 2019+9.9%+16.4%+26.5%
Q2 2019+18.4%+26.0%+30.0%
Q1 2019+14.0%+20.9%+29.4%
Q4 2018+5.1%+7.7%+6.6%
Q3 2018+0.4%-2.4%-4.9%
Q2 2018+2.4%+2.6%+24.3%
Q1 2018-3.6%-4.3%+9.0%
Q4 2017+3.6%-1.1%+8.6%
Q3 2017+18.9%+22.7%+21.0%
Q2 2017+6.5%+8.6%+15.5%
Q1 2017-5.8%-4.6%+0.9%
Q4 2016-5.2%+0.7%-7.2%
Q3 2016+9.9%+10.3%+3.9%
Q2 2016+18.5%+23.3%+22.2%
Q1 2016-4.0%
Q4 2015+9.0%
Q3 2015+13.2%
Q2 2015+10.0%
Q1 2015-11.0%
Q4 2014-4.5%
Q3 2014+5.1%
Q2 2014-2.2%
Q1 2014-14.0%
Q3 2013-3.4%
Q2 2013+10.2%
Q1 2013+12.0%
Q4 2012+9.3%
Q3 2012+4.2%
Q2 2012+4.8%
Q1 2012+2.1%
Q4 2011-3.5%
Q3 2011+0.5%
Q2 2011+2.9%
Q1 2011+0.6%
Q4 2010-2.0%
Q3 2010+2.5%
Q2 2010+0.3%
Q1 2010+11.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro